Full-text article available only as a pdf file for download
Control of asthma in adults treated with beclomethasone and formoterol in extrafine particle formulation in a real-life setting in Poland: the CASPER noninterventional, observational trial
DOI: 10.20452/pamw.3111
Published online: September 24, 2015
INTRODUCTION Asthma is one of the most common health problems, and its poor control can seriously
affect patients’ lives.
OBJECTIVES We assessed the level of asthma control in a real-life setting in Poland, in outpatients treated
with a beclomethasone and formoterol combination pressurized metered-dose inhaler (BDP/F-pMDI).
PATIENTS AND METHODS The study lasted for 6 months (3 visits). Patients were aged 18 years or older,
were diagnosed with asthma at least 12 months before the inclusion to the study, and had been using
BDP/F-pMDI hydrofluoroalkanes (HFA) for a minimum of 2 weeks before the enrollment. Asthma control
was determined in accordance with the criteria of the Global Initiative for Asthma. Patients’ data were
collected during study visits, using unified questionnaires with close-ended questions.
RESULTS During the first visit, 8.6% of the patients had controlled asthma; 27.6%, partly controlled
asthma; and 63.9%, uncontrolled asthma. Poorer control of asthma was observed in men, smokers,
patients with a longer history of asthma, higher body mass index, lower physical activity, shorter treatment
with BDP/F-pMDI HFA, and inaccurate inhaler technique. After 6 months of therapy, asthma control
improved in 74.2% of the patients; 60.1% of the patients met the criteria of controlled asthma; 31.4%,
of partly controlled asthma; and 8.3%, of uncontrolled asthma.
CONCLUSIONS The use of BDP/F-pMDI HFA was effective in the long-term control of asthma, and one
of the important factors improving treatment outcomes is the training of patients in the correct inhaler
technique.
Download article